PT - JOURNAL ARTICLE AU - Visvabharathy, Lavanya AU - Hanson, Barbara A. AU - Orban, Zachary S. AU - Lim, Patrick H. AU - Palacio, Nicole M. AU - Jimenez, Millenia AU - Clark, Jeffrey R. AU - Graham, Edith L. AU - Liotta, Eric M. AU - Tachas, George AU - Penaloza-MacMaster, Pablo AU - Koralnik, Igor J. TI - T cell responses to SARS-CoV-2 in people with and without neurologic symptoms of long COVID AID - 10.1101/2021.08.08.21261763 DP - 2022 Jan 01 TA - medRxiv PG - 2021.08.08.21261763 4099 - http://medrxiv.org/content/early/2022/10/21/2021.08.08.21261763.short 4100 - http://medrxiv.org/content/early/2022/10/21/2021.08.08.21261763.full AB - Many people experiencing long COVID syndrome, or post-acute sequelae of SARS-CoV-2 infection (PASC), suffer from debilitating neurologic symptoms (Neuro-PASC). However, whether virus-specific adaptive immunity is affected in Neuro-PASC patients remains poorly understood. We report that Neuro-PASC patients exhibit distinct immunological signatures composed of elevated humoral and cellular responses toward SARS-CoV-2 Nucleocapsid protein at an average of 6 months post-infection compared to healthy COVID convalescents. Neuro-PASC patients also had enhanced virus-specific production of IL-6 from and diminished activation of CD8+ T cells. Furthermore, the severity of cognitive deficits or quality of life disturbances in Neuro-PASC patients were associated with a reduced diversity of effector molecule expression in T cells but elevated IFN-γ production to the C-terminal domain of Nucleocapsid protein. Proteomics analysis showed enhanced plasma immunoregulatory proteins and reduced pro-inflammatory and antiviral response proteins in Neuro-PASC patients compared with healthy COVID convalescents, which were also correlated with worse neurocognitive dysfunction. These data provide new insight into the pathogenesis of long COVID syndrome and a framework for the rational design of predictive biomarkers and therapeutic interventions.One Sentence Summary Adaptive immunity is altered in patients with neurologic manifestations of long COVID.Competing Interest StatementThe authors have declared no competing interest.Funding StatementL.V. was supported by a T32 grant T32AR007611 from the Department of Rheumatology, Northwestern University Feinberg School of Medicine. P.P.M. is supported by a grant from the Emerging and Re-Emerging Pathogens Program (EREPP) at Northwestern University, and a grant from the National Institute on Drug Abuse (NIDA, DP2DA051912)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Northwestern University Institutional Review Board (Koralnik Lab, IRB STU00212583).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, [LV], upon reasonable request.